IgE-selective immunoadsorption for severe atopic dermatitis

Michael Kasperkiewicz*, Sophie Charlotte Mook, Diana Knuth-Rehr, Artem Vorobyev, Ralf J. Ludwig, Detlef Zillikens, Philip Muck, Enno Schmidt

*Korrespondierende/r Autor/-in für diese Arbeit
1 Zitat (Scopus)


Introduction: Recent reports proposed the application of immunoadsorption (IA) for patients with recalcitrant atopic dermatitis (AD) and high-serum IgE levels. However, experience with this novel treatment approach, especially with the newly available IgE-specific adsorber, is limited and recommendation for its use in clinical practice awaits evidence from more studies. Materials and methods: Patients with severe AD (SCORAD ≥= 60) and total serum IgE levels ≥750 kU/L were included in this study. The treatment protocol consisted of two cycles of five consecutive treatments with IgE-selective IA 3 weeks apart. Results: Ten patients were enrolled and four patients completed the study. The mean SCORAD was significantly improved by up to 43% within a few weeks and until the end of a 6-month follow-up period, with 50% of patients achieving an at least 50% individual reduction of the baseline SCORAD. Each IA cycle induced a temporal average decrement of total serum levels of IgE, IgM, IgA, and IgG by 92, 43, 38, and 35%, respectively. Except for one case of Staphylococcus aureus septicemia, no major adverse events occurred. Conclusion: Although limited by a considerable withdrawal rate, our observations strengthen our and other recent results further suggesting that IgE-selective IA is an effective treatment option for patients severely affected by AD with highly elevated IgE levels.

ZeitschriftFrontiers in medicine
PublikationsstatusVeröffentlicht - 01.02.2018


Untersuchen Sie die Forschungsthemen von „IgE-selective immunoadsorption for severe atopic dermatitis“. Zusammen bilden sie einen einzigartigen Fingerprint.